Polycystic Ovarian Syndrome
Conditions
Interventions
Two Groups:Group 1 oral (medroxyprogesterone acetate) MPA 10 mg daily for 10 days for every month for the first 4 months, followed by a washout period of 4 months, and then diane-35 one tablet daily f
Sponsors
None listed
Eligibility
Sex/Gender
Male
Age
14 Years to 19 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients aged 14 to 19 and diagnosed PCOS in the Gynaecology clinics of AHNH and PWH. The diagnosis of PCOS is based on the Rotterdam consensus on diagnostic criteria for PCOS; that is, at least 2 out of 3 of the following criteria: 1. Oligo- and / or anovulation; 2. Clinical and / or biochemical signs of hyperandrogenism; 3. Ultrasound appearance of polycystic ovaries; and exclusion of other aetiologies.
Exclusion criteria
Exclusion criteria: Exclusion criteria are: 1. patient who has fertility wish; 2. confirmed concomitant diabetics mellitus which may need other medical treatment for PCOS; 3. significant liver impairment or other medical condition that is contraindicated for MPA or diane-35; and 4. previous use of hormonal treatment in the past 4 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is the psychological well being of the subjects on the different treatments, using a standard questionnaire 36-item Short Form Health Survey (SF-36) and a client satisfaction questionnaire. They will be assessed during every visit (ie at baseline, 4 month, 8 month & 12 month of study); | — |
Secondary
| Measure | Time frame |
|---|---|
| All of the following will be assessed or measured during every visit (ie at baseline, 4 month, 8 month & 12 month of study) 1. Menstrual pattern and any abnormal bleeding throughout the study period.;2. Clinical parameters including body mass index, blood pressure, waist-to-hip circumference ratio, scoring on acne and hirsutism.;3. Hormonal profile by measurements of serum concentrations of luteinizing hormone, follicular stimulating hormone, oestradiol, testosterone, sex hormone binding globulin, and androstenedione.; | — |
Countries
China
Contacts
Public ContactDr Chan Shing Chee, Symphorosa
Outcome results
None listed